
Mohammad M. Hoque
Examiner (ID: 9407, Phone: (571)272-6266 , Office: P/2817 )
| Most Active Art Unit | 2817 |
| Art Unit(s) | 2817, 2823 |
| Total Applications | 844 |
| Issued Applications | 653 |
| Pending Applications | 100 |
| Abandoned Applications | 113 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17592557
[patent_doc_number] => 20220142130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => Targeting Vector, Nucleic Acid Composition, and Method for Constructing Liver-injured Mouse Model
[patent_app_type] => utility
[patent_app_number] => 17/611882
[patent_app_country] => US
[patent_app_date] => 2020-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/611882 | Targeting Vector, Nucleic Acid Composition, and Method for Constructing Liver-injured Mouse Model | Oct 19, 2020 | Abandoned |
Array
(
[id] => 18056460
[patent_doc_number] => 20220387546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => Methods For Treating And/Or Preventing Hypersomnias
[patent_app_type] => utility
[patent_app_number] => 17/770406
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770406
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770406 | Methods For Treating And/Or Preventing Hypersomnias | Oct 14, 2020 | Abandoned |
Array
(
[id] => 18018111
[patent_doc_number] => 20220369610
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => HIGH FREQUENCY TARGETED ANIMAL TRANSGENESIS
[patent_app_type] => utility
[patent_app_number] => 17/767311
[patent_app_country] => US
[patent_app_date] => 2020-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -50
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767311
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767311 | HIGH FREQUENCY TARGETED ANIMAL TRANSGENESIS | Oct 7, 2020 | Pending |
Array
(
[id] => 18018109
[patent_doc_number] => 20220369608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => METHOD FOR ESTABLISHING DIABETES DISEASE MODEL DOG
[patent_app_type] => utility
[patent_app_number] => 17/762629
[patent_app_country] => US
[patent_app_date] => 2020-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762629
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/762629 | METHOD FOR ESTABLISHING DIABETES DISEASE MODEL DOG | Sep 22, 2020 | Abandoned |
Array
(
[id] => 17958666
[patent_doc_number] => 20220339246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => COMPOSITIONS INCLUDING MOLECULES OF MODIFIED MRNA AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/753660
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753660
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753660 | COMPOSITIONS INCLUDING MOLECULES OF MODIFIED MRNA AND METHODS OF USING THE SAME | Sep 10, 2020 | Pending |
Array
(
[id] => 17943513
[patent_doc_number] => 20220330530
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => METHOD OF MAKING HUMAN MOUSE XENOGRAFTS
[patent_app_type] => utility
[patent_app_number] => 17/642768
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642768
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642768 | METHOD OF MAKING HUMAN MOUSE XENOGRAFTS | Sep 10, 2020 | Abandoned |
Array
(
[id] => 17980321
[patent_doc_number] => 20220346357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2
[patent_app_type] => utility
[patent_app_number] => 17/640592
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21698
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/640592 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TNFR2 | Sep 3, 2020 | Pending |
Array
(
[id] => 17865500
[patent_doc_number] => 20220288235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
[patent_app_type] => utility
[patent_app_number] => 17/636152
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23548
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636152
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/636152 | SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY | Aug 18, 2020 | Pending |
Array
(
[id] => 16437094
[patent_doc_number] => 20200354420
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM
[patent_app_type] => utility
[patent_app_number] => 16/940277
[patent_app_country] => US
[patent_app_date] => 2020-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16940277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/940277 | GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM | Jul 26, 2020 | Abandoned |
Array
(
[id] => 17988061
[patent_doc_number] => 20220354098
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => Genetically Modified Non-Human Animals and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/626903
[patent_app_country] => US
[patent_app_date] => 2020-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34163
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626903
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/626903 | Genetically Modified Non-Human Animals and Methods of Use Thereof | Jul 16, 2020 | Pending |
Array
(
[id] => 16541275
[patent_doc_number] => 20200407688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => Osteogenic Differentiation of Bone Marrow Stem Cells and Mesenchymal Stem Cells Using a Combination of Growth Factors
[patent_app_type] => utility
[patent_app_number] => 16/929042
[patent_app_country] => US
[patent_app_date] => 2020-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929042
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/929042 | Osteogenic Differentiation of Bone Marrow Stem Cells and Mesenchymal Stem Cells Using a Combination of Growth Factors | Jul 13, 2020 | Abandoned |
Array
(
[id] => 19361160
[patent_doc_number] => 20240263194
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => ANIMAL PREPARATION METHOD
[patent_app_type] => utility
[patent_app_number] => 17/909294
[patent_app_country] => US
[patent_app_date] => 2020-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17909294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/909294 | ANIMAL PREPARATION METHOD | Jul 12, 2020 | Pending |
Array
(
[id] => 17760110
[patent_doc_number] => 20220233722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => cPLA2e INDUCING AGENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/624178
[patent_app_country] => US
[patent_app_date] => 2020-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624178
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/624178 | cPLA2e INDUCING AGENTS AND USES THEREOF | Jun 29, 2020 | Pending |
Array
(
[id] => 18056542
[patent_doc_number] => 20220387628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/618779
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 142029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618779
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/618779 | MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND USES THEREOF | Jun 23, 2020 | Abandoned |
Array
(
[id] => 16396422
[patent_doc_number] => 20200337280
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => Animal Models and Therapeutic Molecules
[patent_app_type] => utility
[patent_app_number] => 16/905537
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905537
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/905537 | Animal Models and Therapeutic Molecules | Jun 17, 2020 | Pending |
Array
(
[id] => 16434820
[patent_doc_number] => 20200352145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => Animal Models and Therapeutic Molecules
[patent_app_type] => utility
[patent_app_number] => 16/905557
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905557
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/905557 | Animal Models and Therapeutic Molecules | Jun 17, 2020 | Abandoned |
Array
(
[id] => 17943515
[patent_doc_number] => 20220330532
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => NON-HUMAN ANIMALS HAVING A LIMITED LAMBDA LIGHT CHAIN REPERTOIRE EXPRESSED FROM THE KAPPA LOCUS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/616295
[patent_app_country] => US
[patent_app_date] => 2020-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70924
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616295 | NON-HUMAN ANIMALS HAVING A LIMITED LAMBDA LIGHT CHAIN REPERTOIRE EXPRESSED FROM THE KAPPA LOCUS AND USES THEREOF | Jun 3, 2020 | Pending |
Array
(
[id] => 17749671
[patent_doc_number] => 20220227875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => VECTOR-BASED THERAPY FOR THYROID DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/615041
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615041
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/615041 | VECTOR-BASED THERAPY FOR THYROID DISEASE | May 28, 2020 | Abandoned |
Array
(
[id] => 17760109
[patent_doc_number] => 20220233721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING DMPK GENE
[patent_app_type] => utility
[patent_app_number] => 17/614461
[patent_app_country] => US
[patent_app_date] => 2020-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614461
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/614461 | METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING DMPK GENE | May 26, 2020 | Pending |
Array
(
[id] => 17734730
[patent_doc_number] => 20220220189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS
[patent_app_type] => utility
[patent_app_number] => 17/613368
[patent_app_country] => US
[patent_app_date] => 2020-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613368
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/613368 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS | May 21, 2020 | Abandoned |